脂肪性肝病(MASLD、MetALD与ALD)患者结直肠癌发病率
这项全国性队列研究纳入1497813例MASLD、MetALD或ALD患者及4885536例无已知肝病对照,比较各组结直肠癌发病率。ALD组5年及10年累积发病率最高(0.43%和0.97%),其次为MetALD(0.32%和0.73%)和MASLD(0.22%和0.48%),对照组为0.15%和0.31%。调整混杂因素后,ALD、MetALD和MASLD组结直肠癌风险均高于对照组。
要点
- ALD组结直肠癌累积发病率最高,显著高于MetALD、MASLD及对照组(均P<.001)。
- 调整后ALD组结直肠癌风险为对照组的1.73倍(95%CI 1.59-1.87)。
- MetALD组和MASLD组调整后风险分别为对照组的1.36倍和1.28倍。
核心结论
- 脂肪性肝病患者结直肠癌风险存在显著差异,ALD组发病率最高,其次为MetALD和MASLD。
研究设计与样本
- 全国性、基于人群的队列研究,纳入1497813例MASLD、MetALD或ALD患者及4885536例无已知肝病对照。
主要发现
- 5年和10年累积结直肠癌发病率:MASLD组0.22%和0.48%,MetALD组0.32%和0.73%,ALD组0.43%和0.97%,对照组0.15%和0.31%。
- ALD组累积发病率显著高于MetALD、MASLD及对照组(均P<.001)。
- 以对照组为参照,调整年龄、性别、吸烟习惯、结肠镜检查次数、糖尿病、血脂异常、高血压及用药后,ALD组调整风险比1.73(95%CI 1.59-1.87),MetALD组1.36(95%CI 1.28-1.45),MASLD组1.28(95%CI 1.22-1.35)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Obesity and alcohol consumption are established risk factors for colorectal cancer (CRC). Recently, a multisociety consensus group has introduced a new classification for steatotic liver disease (SLD), which encompasses metabolic dysfunction-associated steatotic liver disease (MASLD), MASLD and increased alcohol intake (MetALD), and alcohol-associated liver disease (ALD). However, the risk of developing CRC in each of these SLD subgroups is unknown. This nationwide cohort study investigated the risk of CRC in MASLD, MetALD, and ALD patients. The primary endpoint was the occurrence of CRC in each SLD subgroup. METHODS: We conducted a nationwide, population-based study that included 1,497,813 patients diagnosed with MASLD, MetALD, or ALD, alongside 4,885,536 individuals with no known liver disease as a comparison group. The primary outcome was the incidence of CRC and the risk of CRC was compared between MASLD, MetALD and ALD. RESULTS: The 5- and 10-year cumulative CRC incidence rates were 0.22% and 0.48% for MASLD, 0.32% and 0.73% for MetALD, and 0.43% and 0.97% for ALD, and 0.15% and 0.31% for the comparison group, respectively. The cumulative incidence of CRC was highest for ALD and significantly greater than that for MetALD, MASLD, and the comparison group (both P < .001). Using the comparison group as the reference and adjusting for age, sex, smoking habit, number of colorectal examinations, diabetes mellitus, dyslipidemia, hypertension, and medication use, the adjusted hazard ratios for CRC were 1.73 (95% CI, 1.59-1.87) for ALD, 1.36 (95% CI, 1.28-1.45) for MetALD, and 1.28 (95% CI, 1.22-1.35) for MASLD. CONCLUSIONS: The risk of CRC differs significantly among patients with SLD, with the highest incidence observed in those with ALD, followed by MetALD and MASLD.
引用
- Kimura T, Tamaki N, Wakabayashi SI, et al. Colorectal Cancer Incidence in Steatotic Liver Disease (MASLD, MetALD, and ALD). Clin Gastroenterol Hepatol. 2025. PMID: 39892626. doi:10.1016/j.cgh.2024.12.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。